Vyome Biosciences, a New Delhi, India-based clinical-stage specialty biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, raised $14m in Series C financing.
The round was led by Perceptive Advisors, a New York-based life sciences fund, and Romulus Capital, a Boston-based venture capital firm, with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital.
The company intends to use the funds to advance the clinical development of its lead product, VB 1953, while continuing to develop other proprietary products in its pipeline.
Led by Venkateswarlu Nelabhotla (N. Venkat), Co-Founder & CEO, and Dr. Shiladitya Sengupta, Co-Founder, Vyome Biosciences is developing a pipeline of novel drugs for antibiotic resistant acne, other opportunistic pathogens and antifungal agents in Dermatology. Its lead program is VB 1953 for the treatment of antibiotic resistant acne, which recently received FDA acceptance.